Nutriband Stock Soars to 52-Week High of $9.6 Amidst Strong Growth
Nutriband Inc. (NTRB) shares have surged to a 52-week high, reaching a price level of $9.6, with an impressive 80% gain just ...
Monthly Prescribing Reference2h
FDA Extends Review of Elamipretide for Barth Syndrome
The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.
Biogen Inc.: FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose ...
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...